Histone deacetylase inhibitors and colorectal cancer: what is new?
about
Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane- and dextran sulfate sodium-treated CF-1 mice.Global histone modification fingerprinting in human cells using epigenetic reverse phase protein array.HDAC inhibitors show differential epigenetic regulation and cell survival strategies on p53 mutant colon cancer cells.First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
P2860
Histone deacetylase inhibitors and colorectal cancer: what is new?
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Histone deacetylase inhibitors and colorectal cancer: what is new?
@en
type
label
Histone deacetylase inhibitors and colorectal cancer: what is new?
@en
prefLabel
Histone deacetylase inhibitors and colorectal cancer: what is new?
@en
P2093
P1476
Histone deacetylase inhibitors and colorectal cancer: what is new?
@en
P2093
Athanasios Tampakis
Ekaterini C Tampaki
Gregory Kouraklis
P304
P356
10.2174/1871520614666140919095828
P577
2014-01-01T00:00:00Z